2019年10月13日(日) 08:40 〜 10:20 第16会場 (平安)

Organizer / Chair: ‌Masanori ISOBE (Department of Psychiatry, Kyoto University, Japan, / Department of Psychiatry, University of Cambridge, UK), Co-chair: Masumi INAGAKI (National Institute of Mental Health, NCNP, Japan), Discussants: ‌Yuta AOKI (Medical Institute of Developmental Disabilities Research, Showa University, Japan), Atsushi SATO (Department of Pediatrics, The University of Tokyo Hospital, Japan)

Attention deficit and hyperactivity disorder (ADHD) is a well-known developmental disorder with manifestation of attention deficit, hyperactivity and impulsivity. Substantial progress of drug development has been achieved in ADHD, although many have been serendipitously discovered. Given that cognitive characteristics of ADHD are measurable in animal models and medications are highly effective in patients, ADHD represents a good disease model for translational research. Using a neuropsychopharmacological approach, researchers can gain a greater understanding of the neuronal mechanism of each cognitive symptom and potentially develop new drug treatments. For example, recent studies have shown the baseline-dependent effects of ADHD drugs on attention or impulsivity in animal models, and the difference could be explained at the neuronal and neurochemical levels.
This symposium will introduce recent progress of clinical and non-clinical ADHD researches, and aims to describe what has been achieved and what is to be achieved in translational research of ADHD.
The session will also enable a fruitful discussion regarding transparency and mutual exchange between clinical and non-clinical researchers. This should facilitate greater understanding of how translational methods can disentangle pathological physiology of psychiatric disorders with cognitive deficits, through shared pharmacological effects on cognitive behavior.